Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Apple Restores Telegram to App Store After Content Policy Violation 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SANTA MONICA, Calif., March 19, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20-21 at the Westin Grand Central Hotel in New York City.
| Presentation Details | ||
| Date: | Wednesday, March 21 | |
| Time: | 1:00pm Eastern Time | |
| Location: | Westin Grand Central Hotel, Track 3 | |
| Webcast: | https://ir.opiant.com | |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.
CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 535-7746
